[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-437573-105":59,"doc-detail-437573-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","european-standard-clinical-practice-recommendations-for-non-hodgkin-lymphoma-of-childhood-and-adolescence-version-10-04102021","European Standard Clinical Practice Recommendations - For Non-Hodgkin Lymphoma of Childhood and Adolescence - Version 1.0 - 04.10.2021","","European Standard Clinical Practice Recommendations for childhood and adolescence non-Hodgkin lymphoma outline evidence-based guidance for background, diagnostic criteria, staging, and treatment planning. The document grounds recommendations in NHL-BFM 95 and EICNHL EURO LB 2002 trials, registry data, and relevant international study trials. It details diagnostic approaches, processing of tissue and specimens, definitions of organ involvement, and treatment specifics across lymphoblastic lymphoma, mature aggressive B-cell lymphoma/leukemia, and anaplastic large cell lymphoma. It also provides treatment assessments, adverse event summaries, and dose modification recommendations for key drugs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/european-standard-clinical-practice-recommendations-for-non-hodgkin-lymphoma-of-childhood-and-adolescence-version-10-04102021/437573/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/european-standard-clinical-practice-recommendations-for-non-hodgkin-lymphoma-of-childhood-and-adolescence-version-10-04102021/437573.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What evidence sources does the recommendations document rely on?","Question",{"text":112,"@type":113},"Recommendations are based on NHL-BFM 95 and EICNHL EURO LB 2002 trials, the NHL-BFM registry, and specific international trials including rituximab for high-risk mature B-NHL and EICNHL ALCL99.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What topics are covered under patient group and diagnostics?",{"text":117,"@type":113},"It covers diagnostic criteria, classification of non-Hodgkin lymphoma, diagnostic approach and surgery, processing of tissue and specimens, initial diagnostics, definitions of organ involvement, and staging.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the document handle treatment details and safety during therapy?",{"text":121,"@type":113},"It provides treatment details by disease subtype, assessments during treatment, and a summary of known adverse events with treatment recommendations and dose modifications for multiple drugs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},437573,1790790944,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","EUROPEAN STANDARD CLINICAL PRACTICE RECOMMENDATIONS  \nFOR NON-HODGKIN LYMPHOMA OF CHILDHOOD AND ADOLESCENCE  \nVASILIKI TZOTZOLA (YOUNG SIOPE)  \nPAULA PEREZ (YOUNG SIOPE)  \nAND  \nANDISHE ATTARBASCHI  \non behalf of the  \nEuropean Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the International Berlin-Frankfurt-Münster (i-BFM) Study Group  \nAuke Beishuizen (Chair of EICNHL)  \nKarin Mellgren (Co-Chair of EICNHL)  \nSuzanne D. Turner (Co-Chair of EICNHL)  \nAndishe Attarbaschi (Co-Chair of EICNHL and i-BFM NHL Committee Chair)  \nRecommendations are based on:  \nNHL-BFM 95 and EICNHL EURO LB 2002 TRIALS  \nNHL-BFM REGISTRY  \nINTERNATIONAL RITUXIMAB TRIAL for HIGH-RISK MATURE B-NHL (EICNHL, COG)  \nEICNHL ALCL99 TRIAL  \nVersion 1.0 , 04.10.2021  \nThe ERN PaedCan received funding by the European Union’s Health Programme (2014-2020), grant agreement nr. 847032. Version 1.0, 8.7.2020  \nChildhood and adolescent NHL Standard Clinical Practice document  \nTABLE OF CONTENTS  \nTable of contents...................................................................................................................................2  \nList of abbreviations .............................................................................................................................4  \n1. Background and Rationale..............................................................................................................6  \n1.1 Lymphoblastic Lymphoma...................................................................................................7  \n1.2 Mature Aggressive B-Cell Lymphoma/Leukemia ...............................................................8  \n1.3 Anaplastic Large Cell Lymphoma ..................................................................................... 12  \n2. Patient Group and Diagnostics..................................................................................................... 14  \n2.1 Diagnostic Criteria .............................................................................................................. 14  \n2.1.1 Classification of NHL ......................................................................................................... 14  \n2.1.2 Diagnostic approach and surgery ...................................................................................... 15  \n2.1.3 Processing of tissue and cell specimens ........................................................................... 16  \n2.1.4 Initial diagnostics ............................................................................................................... 16  \n2.1.5 Definition of organ involvement ......................................................................................... 17  \n2.1.6 Staging ............................................................................................................................... 18  \n3. Treatment details ...........................................................................................................................20  \n3.1 Lymphoblastic lymphoma ..................................................................................................20  \n3.2 Mature aggressive B-cell lymphoma/ leukemia ...............................................................22  \n3.2.1 Therapeutic groups and treatment schemes according to the NHL-BFM concept: ...........22  \n3.2.2 Therapeutic groups and treatment schemes according to the European Intergroup for Children Non-Hodgkin Lymphoma (EICNHL) concept: ..................................................................25  \n3.3 Anaplastic Large Cell Lymphoma .....................................................................................28  \n3.4 Assessments during treatment .........................................................................................29  \n3.5 Summary of known adverse events, treatment recommendation and dose modifications ......................................................................","cbCainuKgYyeoMjl","https://ap.wps.com/l/cbCainuKgYyeoMjl","pdf",1083651,45,"English","# Background and Rationale\n## Lymphoblastic Lymphoma\n## Mature Aggressive B-Cell Lymphoma/Leukemia\n## Anaplastic Large Cell Lymphoma\n# Patient Group and Diagnostics\n## Diagnostic Criteria\n## Classification of NHL\n## Diagnostic approach and surgery\n## Processing of tissue and cell specimens\n## Initial diagnostics\n## Definition of organ involvement\n## Staging\n# Treatment details\n## Lymphoblastic lymphoma\n## Mature aggressive B-cell lymphoma/ leukemia\n## Anaplastic Large Cell Lymphoma\n## Assessments during treatment\n## Summary of known adverse events, treatment recommendation and dose modifications","[{\"question\":\"What evidence sources does the recommendations document rely on?\",\"answer\":\"Recommendations are based on NHL-BFM 95 and EICNHL EURO LB 2002 trials, the NHL-BFM registry, and specific international trials including rituximab for high-risk mature B-NHL and EICNHL ALCL99.\"},{\"question\":\"What topics are covered under patient group and diagnostics?\",\"answer\":\"It covers diagnostic criteria, classification of non-Hodgkin lymphoma, diagnostic approach and surgery, processing of tissue and specimens, initial diagnostics, definitions of organ involvement, and staging.\"},{\"question\":\"How does the document handle treatment details and safety during therapy?\",\"answer\":\"It provides treatment details by disease subtype, assessments during treatment, and a summary of known adverse events with treatment recommendations and dose modifications for multiple drugs.\"}]","European Standard Clinical Practice Recommendations - For Non-Hodgkin Lymphoma of Childhood and Adolescence - Version 1.0 - 04.10.2021 | PDF",1790682405,113]